Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1991 Sep;32(3):303–310. doi: 10.1111/j.1365-2125.1991.tb03903.x

Direct and metabolism-dependent toxicity of sulphasalazine and its principal metabolites towards human erythrocytes and leucocytes.

M Pirmohamed 1, M D Coleman 1, F Hussain 1, A M Breckenridge 1, B K Park 1
PMCID: PMC1368522  PMID: 1685664

Abstract

1. The role of metabolites in sulphasalazine-mediated toxicity has been investigated in vitro by the use of human red blood cells and mononuclear leucocytes as target cells, with methaemoglobin formation and cytotoxicity respectively, being the defined toxic end-points. 2. Of the metabolites of sulphasalazine investigated, only sulphapyridine was bioactivated by human liver microsomes in the presence of NADPH to a metabolite which caused marked methaemoglobinaemia and a small, but statistically significant degree of mononuclear leucocyte cell death. 3. Methaemoglobinaemia was inhibited by ketoconazole but not by ascorbic acid (100 microM), glutathione (500 microM) and N-acetylcysteine (50 microM). In contrast, ascorbic acid and the thiols afforded complete protection for mononuclear leucocytes. 4. Sulphapyridine (100 microM) was converted in vitro to a metabolite (metabolite conversion 6.8 +/- 0.3%), the retention time of which on h.p.l.c. corresponded to synthetic sulphapyridine hydroxylamine. The half-life of sulphapyridine hydroxylamine in phosphate buffer (pH 7.4) was found to be 8.1 min. 5. In the absence of microsomes and NADPH, sulphapyridine hydroxylamine caused a concentration-dependent (10-500 microM) increase in methaemoglobinaemia (2.9%-24.4%) and cytotoxicity (5.4%-51.4%), whereas sulphasalazine, sulphapyridine, 5-hydroxy sulphapyridine and 5-aminosalicylic acid had no effect.

Full text

PDF
303

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amos R. S., Bax D. E. Leucopenia in rheumatoid arthritis: relationship to gold or sulphasalazine therapy. Br J Rheumatol. 1988 Dec;27(6):465–468. doi: 10.1093/rheumatology/27.6.465. [DOI] [PubMed] [Google Scholar]
  2. Bondesen S., Schou J. B., Pedersen V., Rafiolsadat Z., Hansen S. H., Hvidberg E. F. Absorption of 5-aminosalicylic acid from colon and rectum. Br J Clin Pharmacol. 1988 Feb;25(2):269–272. doi: 10.1111/j.1365-2125.1988.tb03301.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Coleman M. D., Breckenridge A. M., Park B. K. Bioactivation of dapsone to a cytotoxic metabolite by human hepatic microsomal enzymes. Br J Clin Pharmacol. 1989 Oct;28(4):389–395. doi: 10.1111/j.1365-2125.1989.tb03517.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Das K. M., Dubin R. Clinical pharmacokinetics of sulphasalazine. Clin Pharmacokinet. 1976 Nov-Dec;1(6):406–425. doi: 10.2165/00003088-197601060-00002. [DOI] [PubMed] [Google Scholar]
  5. Das K. M., Eastwood M. A., McManus J. P., Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med. 1973 Sep 6;289(10):491–495. doi: 10.1056/NEJM197309062891001. [DOI] [PubMed] [Google Scholar]
  6. Deprez P., Descamps C., Fiasse R. Pancreatitis induced by 5-aminosalicylic acid. Lancet. 1989 Aug 19;2(8660):445–446. doi: 10.1016/s0140-6736(89)90620-x. [DOI] [PubMed] [Google Scholar]
  7. EVANS R. S., FORD W. P., Jr Studies of the bone marrow in immunological granulocytopenia; following administration of salicylazosulfapyridine. AMA Arch Intern Med. 1958 Feb;101(2):244–251. doi: 10.1001/archinte.1958.00260140076012. [DOI] [PubMed] [Google Scholar]
  8. Eyer P. Detoxication of N-oxygenated arylamines in erythrocytes. An overview. Xenobiotica. 1988 Nov;18(11):1327–1333. doi: 10.3109/00498258809042257. [DOI] [PubMed] [Google Scholar]
  9. Eyer P. The red cell as a sensitive target for activated toxic arylamines. Arch Toxicol Suppl. 1983;6:3–12. doi: 10.1007/978-3-642-69083-9_1. [DOI] [PubMed] [Google Scholar]
  10. Farr M., Symmons D. P., Bacon P. A. Raised serum alkaline phosphatase and aspartate transaminase levels in two rheumatoid patients treated with sulphasalazine. Ann Rheum Dis. 1985 Nov;44(11):798–800. doi: 10.1136/ard.44.11.798. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Farr M., Tunn E. J., Symmons D. P., Scott D. G., Bacon P. A. Sulphasalazine in rheumatoid arthritis: haematological problems and changes in haematological indices associated with therapy. Br J Rheumatol. 1989 Apr;28(2):134–138. doi: 10.1093/rheumatology/28.2.134. [DOI] [PubMed] [Google Scholar]
  12. Fischer C., Klotz U. Determination of sulfapyridine and its major metabolites in plasma by high pressure liquid chromatography. J Chromatogr. 1978 Jul 1;146(1):157–162. doi: 10.1016/s0378-4347(00)81302-x. [DOI] [PubMed] [Google Scholar]
  13. Grossman S. J., Jollow D. J. Role of dapsone hydroxylamine in dapsone-induced hemolytic anemia. J Pharmacol Exp Ther. 1988 Jan;244(1):118–125. [PubMed] [Google Scholar]
  14. Harrison J. H., Jr, Jollow D. J. Role of aniline metabolites in aniline-induced hemolytic anemia. J Pharmacol Exp Ther. 1986 Sep;238(3):1045–1054. [PubMed] [Google Scholar]
  15. Kiese M. The biochemical production of ferrihemoglobin-forming derivatives from aromatic amines, and mechanisms of ferrihemoglobin formation. Pharmacol Rev. 1966 Sep;18(3):1091–1161. [PubMed] [Google Scholar]
  16. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  17. Mechanick J. I. Coombs' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review, and discussion of pathogenesis. Mt Sinai J Med. 1985 Oct;52(8):667–670. [PubMed] [Google Scholar]
  18. Neumann V. C., Grindulis K. A., Hubball S., McConkey B., Wright V. Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial. Br Med J (Clin Res Ed) 1983 Oct 15;287(6399):1099–1102. doi: 10.1136/bmj.287.6399.1099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Pounder R. E., Craven E. R., Henthorn J. S., Bannatyne J. M. Red cell abnormalities associated with sulphasalazine maintenance therapy for ulcerative colitis. Gut. 1975 Mar;16(3):181–185. doi: 10.1136/gut.16.3.181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Prosiegel M., Neu I., Ruhenstroth-Bauer G., Hoffmann G., Vogl S., Mehlber L., Wildfeuer A. Suppression of experimental autoimmune encephalitis by sulfasalazine. N Engl J Med. 1989 Aug 24;321(8):545–546. doi: 10.1056/NEJM198908243210817. [DOI] [PubMed] [Google Scholar]
  21. Pullar T., Hunter J. A., Capell H. A. Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate. Br Med J (Clin Res Ed) 1983 Oct 15;287(6399):1102–1104. doi: 10.1136/bmj.287.6399.1102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Pullar T., Hunter J. A., Capell H. A. Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy. Br J Rheumatol. 1985 Aug;24(3):269–276. doi: 10.1093/rheumatology/24.3.269. [DOI] [PubMed] [Google Scholar]
  23. Pullar T. Sulphasalazine and related drugs in rheumatoid arthritis. Pharmacol Ther. 1989;42(3):459–468. doi: 10.1016/0163-7258(89)90035-1. [DOI] [PubMed] [Google Scholar]
  24. Purba H. S., Maggs J. L., Orme M. L., Back D. J., Park B. K. The metabolism of 17 alpha-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites. Br J Clin Pharmacol. 1987 Apr;23(4):447–453. doi: 10.1111/j.1365-2125.1987.tb03074.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Rieder M. J., Uetrecht J., Shear N. H., Cannon M., Miller M., Spielberg S. P. Diagnosis of sulfonamide hypersensitivity reactions by in-vitro "rechallenge" with hydroxylamine metabolites. Ann Intern Med. 1989 Feb 15;110(4):286–289. doi: 10.7326/0003-4819-110-4-286. [DOI] [PubMed] [Google Scholar]
  26. Riley R. J., Maggs J. L., Lambert C., Kitteringham N. R., Park B. K. An in vitro study of the microsomal metabolism and cellular toxicity of phenytoin, sorbinil and mianserin. Br J Clin Pharmacol. 1988 Nov;26(5):577–588. doi: 10.1111/j.1365-2125.1988.tb05298.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Riley S. A., Turnberg L. A. Sulphasalazine and the aminosalicylates in the treatment of inflammatory bowel disease. Q J Med. 1990 Jun;75(278):551–562. [PubMed] [Google Scholar]
  28. Roberts S. M., Adams L. E., Donovan-Brand R., Budinsky R., Skoulis N. P., Zimmer H., Hess E. V. Procainamide hydroxylamine lymphocyte toxicity--I. Evidence for participation by hemoglobin. Int J Immunopharmacol. 1989;11(4):419–427. doi: 10.1016/0192-0561(89)90089-1. [DOI] [PubMed] [Google Scholar]
  29. Safer B., Grunberg-Manago M., Badman D., Bergman F., Freeman C., Galasso G., Jagus R., Williams B. International symposium on translational/transcriptional regulation of gene expression. Highlights of the Fogarty International Center Meeting held in Bethesda, Maryland on 7-9 April, 1982. FEBS Lett. 1982 Oct 4;147(1):1–10. doi: 10.1016/0014-5793(82)81000-4. [DOI] [PubMed] [Google Scholar]
  30. Shear N. H., Spielberg S. P. In vitro evaluation of a toxic metabolite of sulfadiazine. Can J Physiol Pharmacol. 1985 Nov;63(11):1370–1372. doi: 10.1139/y85-225. [DOI] [PubMed] [Google Scholar]
  31. Sheets J. J., Mason J. I. Ketoconazole: a potent inhibitor of cytochrome P-450-dependent drug metabolism in rat liver. Drug Metab Dispos. 1984 Sep-Oct;12(5):603–606. [PubMed] [Google Scholar]
  32. Thomas P., Seaton A., Edwards J. Respiratory disease due to sulphasalazine. Clin Allergy. 1974 Mar;4(1):41–47. doi: 10.1111/j.1365-2222.1974.tb01361.x. [DOI] [PubMed] [Google Scholar]
  33. Tingle M. D., Coleman M. D., Park B. K. An investigation of the role of metabolism in dapsone-induced methaemoglobinaemia using a two compartment in vitro test system. Br J Clin Pharmacol. 1990 Dec;30(6):829–838. doi: 10.1111/j.1365-2125.1990.tb05448.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Uetrecht J. P. Idiosyncratic drug reactions: possible role of reactive metabolites generated by leukocytes. Pharm Res. 1989 Apr;6(4):265–273. doi: 10.1023/a:1015934104984. [DOI] [PubMed] [Google Scholar]
  35. Uetrecht J. P. Reactivity and possible significance of hydroxylamine and nitroso metabolites of procainamide. J Pharmacol Exp Ther. 1985 Feb;232(2):420–425. [PubMed] [Google Scholar]
  36. Uetrecht J., Zahid N., Shear N. H., Biggar W. D. Metabolism of dapsone to a hydroxylamine by human neutrophils and mononuclear cells. J Pharmacol Exp Ther. 1988 Apr;245(1):274–279. [PubMed] [Google Scholar]
  37. Vartdal F., Kvalheim G., Lea T. E., Bosnes V., Gaudernack G., Ugelstad J., Albrechtsen D. Depletion of T lymphocytes from human bone marrow. Use of magnetic monosized polymer microspheres coated with T-lymphocyte-specific monoclonal antibodies. Transplantation. 1987 Mar;43(3):366–371. [PubMed] [Google Scholar]
  38. Wallace I. W. Neurotoxicity associated with a reaction to sulphasalazine. Practitioner. 1970 Jun;204(224):850–851. [PubMed] [Google Scholar]
  39. Woodward D. K. Peripheral neuropathy and mesalazine. BMJ. 1989 Nov 11;299(6709):1224–1224. doi: 10.1136/bmj.299.6709.1224-a. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES